Literature DB >> 18503553

A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.

Andreas Wollenberg, Nicolas Moosmann, Elisabeth Klein, Kerstin Katzer.   

Abstract

Acneiform skin eruptions are the most common side effect of epidermal growth factor receptor (EGFR) inhibitors. The National Cancer Institute Common Toxicity Criteria allow for quick severity estimation of a patient, but are not suitable for monitoring the severity of the skin lesions over time, as needed for treatment studies. Here we present our scoring tool for acneiform skin eruptions, which is calculated from body involvement, facial involvement and clinical grading of the skin items erythema, papulation, pustulation and scaling/crusts. The final score is a number between 0 and 100.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503553     DOI: 10.1111/j.1600-0625.2008.00715.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  13 in total

1.  Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.

Authors:  Carmine Pinto; Carlo Antonio Barone; Giampiero Girolomoni; Elvio Grazioso Russi; Marco Carlo Merlano; Daris Ferrari; Evaristo Maiello
Journal:  Oncologist       Date:  2011-01-27

Review 2.  Cutaneous side effects of new antitumor drugs: clinical features and management.

Authors:  Ralf Gutzmer; Andreas Wollenberg; Selma Ugurel; Bernhard Homey; Arnold Ganser; Alexander Kapp
Journal:  Dtsch Arztebl Int       Date:  2012-02-24       Impact factor: 5.594

Review 3.  [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects].

Authors:  P A Gerber; B A Buhren; S Kürle; B Homey
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

4.  Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.

Authors:  Peter Arne Gerber; Stephan Meller; Tatiana Eames; Bettina Alexandra Buhren; Holger Schrumpf; Sonja Hetzer; Laura Maximiliane Ehmann; Wilfried Budach; Edwin Bölke; Christiane Matuschek; Andreas Wollenberg; Bernhard Homey
Journal:  Eur J Med Res       Date:  2012-02-23       Impact factor: 2.175

5.  Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

Authors:  M E Lacouture
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

6.  [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].

Authors:  L M Ehmann; V Heinemann; A Wollenberg
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

7.  How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?

Authors:  Alexandre Chan; Eng Hooi Tan
Journal:  Support Care Cancer       Date:  2010-09-05       Impact factor: 3.603

8.  Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?

Authors:  Jacopo Giuliani; Marina Marzola
Journal:  J Gastrointest Cancer       Date:  2013-06

9.  Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.

Authors:  Shaad E Abdullah; Missak Haigentz; Bilal Piperdi
Journal:  Chemother Res Pract       Date:  2012-09-11

10.  A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.

Authors:  Janja Ocvirk; Steffen Heeger; Philip McCloud; Ralf-Dieter Hofheinz
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.